<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="799">
  <stage>Registered</stage>
  <submitdate>27/09/2005</submitdate>
  <approvaldate>19/10/2005</approvaldate>
  <actrnumber>ACTRN12605000663651</actrnumber>
  <trial_identification>
    <studytitle>Pravastatin for Hyperlipidaemia in HIV.</studytitle>
    <scientifictitle>A Randomised, Double-blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients with HIV</scientifictitle>
    <utrn />
    <trialacronym>PRAVA</trialacronym>
    <secondaryid>National Heart, Lung, and Blood Institute of the National Institutes of Health: R01 HL65953-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV 
</healthcondition>
    <healthcondition>Lipid metabolism</healthcondition>
    <healthcondition>Glucose metabolism</healthcondition>
    <healthcondition>Metabolic abnormality</healthcondition>
    <healthcondition>Lipodystrophy</healthcondition>
    <healthcondition>Cardiovascular disease</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study is a randomised, placebo-controlled study of the effect of 12 weeks treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The between-group difference in time weighted change from baseline in fasting serum total cholesterol.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>i. between-group difference in time weighted change from week 4 in fasting serum total cholesterol (start of pravastatin).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ii. individual changes in fasting total cholesterol at each measured time point.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>iii. between-group difference in time weighted change from baseline in HDL-cholesterol and triglycerides, change from baseline glucose, insulin.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>iv. between-group difference in change from baseline in total and regional body fat.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>v. between-group difference in change from baseline in endothelial function and peripheral blood markers of cardiovascular risk.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Provide written informed consent to participate in the trial - HIV-1 sero-positive - Currently receiving HIV protease inhibitor therapy for &gt; 12 weeks and unlikely to require change in existing regimen during the 16 week study period- Fasting cholesterol &gt; 6.5 mmol/L (mean of 2 samples collected &gt; 3 days apart)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Gastrointestinal disorder which may affect drug absorption- Hypertension or congestive cardiac failure- Lactic acidemia (serum lactate level &gt;2.2 mmol/L)- Any serious medical condition which may compromise the patients safety, including pancreatitis or hepatitis within past 6 months- Active AIDS defining conditions- Concurrent therapy with any other lipid lowering agents, oral hypoglycaemics, anabolic steroids or insulin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects were randomised on a 1:1 ratio to either active drug or matched placebo. Randomisation was performed by the hospital pharmacy and the study investigators were blinded as to randomised allocation.</concealment>
    <sequence>Randomisation sequence was generated by the study statistician.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>12/07/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Heart Lung and Blood Institute</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>US National Institutes of Health</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>St Vincents Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Sydney Limited</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrick WG Mallon</name>
      <address>National Centre in HIV Epidemiology and Clinical Research (NCHECR)
Level 2
376 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 83823107</phone>
      <fax>+61 2 83822391</fax>
      <email>pmallon@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Andrew D Carr</name>
      <address>National Centre in HIV Epidemiology and Clinical Research (NCHECR)
Level 2
376 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 83823359</phone>
      <fax>+61 2 83822893</fax>
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>